In the News
-
Sealy Institute for Drug Discovery Faculty Focus
Dr. Menachery (@themenacherylab) is an Assistant Professor in the Department of Microbiology & Immunology at UTMB and has been studying coronaviruses (CoVs) since 2010.
-
Seeking outstanding, highly creative scientists as Tenure-Track Investigators
The Vaccine Research Center (VRC), part of the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH), is seeking outstanding, highly creative scientists as Tenure-Track Investigators (equivalent to an assistant or associate professor-level academic faculty) to advance visionary and field-leading basic, translational, and applied research to develop safe and effective novel vaccines and therapeutics against infectious diseases. Expertise in immunology, virology, structural biology, bioengineering, and closely related fields is desired.
-
-
-
5 Tenure-Track Positions at IDD
The first application review will consider applications submitted by March 20, 2023, with additional reviews quarterly until positions are filled. Applications will be accepted with additional reviews quarterly until December 2023.
-
-
Report on Bivalent Vaccine Neutralization
UTMB researchers, led by Pei-Yong Shi and Xuping Xie, report on bivalent vaccine neutralization against new Omicron subvariants in Nature Medicine.
-
Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection
Increasing Community Access to Testing Program, United States, September–November 2022
-
Improved Vaccine Efficacy of the Bivalent Booster Against Omicron Infections
A Year After the Omicron Surge, Officials See a Reduced Covid Threat This Winter
-
UTMB drug discovery partnership awarded $56 milllion grant
Thanks to a $56 million grant, the University of Texas Medical Branch and global health care company Novartis will enhance their work together to discover drugs to fight off the next pandemic.
